GlassScriptPhysician profile
Yuncen A He
NPI 1598127292
$9,480.48
in general payments reported to CMS, 2019-2025
16 companies · $5,432 in 2025
The $5,432 reported for 2025 was more than what 83% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,587 · 2023: $244 · 2024: $2,218 · 2025: $5,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,866 · Travel and Lodging: $3,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,865.50 |
| Travel and Lodging | $3,028.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,072.16 | 2022-2025 | Inspiris Resilia Aortic Valve, Mitris Resilia Mitral Valve |
| Bolton Medical INC | $1,816.58 | 2024-2025 | Treo Abdominal Stent-Graft System, Thoraflex Hybrid, Relay Thoracic Stent-Graft With Plus Delivery System |
| Becton, Dickinson and Company | $1,460.18 | 2025 | Hemosphere |
| Abiomed | $1,187.89 | 2024-2025 | Impella |
| Angiodynamics, INC. | $890.78 | 2024 | Angiovac |
| Artivion, INC. | $784.72 | 2025 | Amds-Ascyrus Medical |
| Atricure, INC. | $367.19 | 2023-2024 | |
| Abbott Laboratories | $299.69 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Baxter Healthcare | $299.21 | 2024-2025 | Preveleak, Perclot |
| Davol INC. | $144.81 | 2024 | Tridyne Vascular Sealant |
| Bridgebio Pharma, INC. | $37.26 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $34.96 | 2024 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $30.39 | 2025 | Livtencity |
| Organogenesis INC. | $22.81 | 2025 | Puraply Wound Matrix |
| La Jolla Pharmaceutical Company | $18.63 | 2024 | Giapreza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.22 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuncen He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.